IRIX Iridex Corp.

Iridex Comments on Recent Stock Price Volatility

Iridex Comments on Recent Stock Price Volatility

MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility.

The company is not aware of any material developments or changes to its operating or financial condition that precipitated the volume and price movements that occurred on March 13, 2025. There have been no material adverse changes to the company’s operating results, its business, strategy, or prospects since the company provided preliminary operating and financial results for the fourth quarter and full year 2024 on January 14, 2025.

Final fourth quarter and full year 2024 financial results will be released and discussed as previously announced on a conference call scheduled for 2:00pm PT on Thursday, March 27, 2025. Investors interested in listening to the conference call may do so by dialing and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at 

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.

Investor Relations Contact:

Philip Taylor

Gilmartin Group



EN
14/03/2025

Underlying

IRIXIridex Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iridex Corp.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
MMLP Martin Midstrea...
MERC Mercer Internat... ... (+13)

InsiderInsights.com Daily Ratings Report: June 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MMLP MARTIN MIDSTREAM PARTNERS L.P.
MERC MERCER INTERNATIONAL INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CABO CABLE ONE INC.
BUSE FIRST BUSEY CORPORATION
IRIX IRIDEX CORP.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
VRA VERA BRADLEY INC.
QTRX QUANTERIX CORPORATION
ULBI ULTRALIFE
DCTH DELCATH SYSTEMS
WHLR WHEELER REAL ESTATE INVESTMENT TRUST INC.
06/14/25 June 14, 2025 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Reports First Quarter 2025 Financial Results

Iridex Reports First Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8%...

May 13, 2025 1 EN
Free Trial
IRIX IRIDEX CORP.

Iridex Corp: 2 directors

A director at Iridex Corp bought 20,000 shares at 1.207USD and the significance rating of the trade was 38/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

05/01/25 May 1, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
LUV SOUTHWEST AIRLI...
TBK Triumph Bancorp... ... (+12)

InsiderInsights.com Daily Ratings Report: April 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

LUV SOUTHWEST AIRLINES CO.
TBK TRIUMPH BANCORP INC.
NBTB NBT BANCORP INC.
MTDR MATADOR RESOURCES COMPANY
IRIX IRIDEX CORP.
SNWV SANUWAVE HEALTH
OVLY OAK VALLEY BANCORP
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
FNLC FIRST BANCORP
DLHC INC (ME)
SUNS DALEIGH HOLDINGS CORP
SUNRISE REALTY TRUST
05/01/25 May 1, 2025 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

Iridex to Report First Quarter 2025 Financial Results on May 13, 2025 MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company’s management team will host a corresponding conference call beginning at...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch